Citations

Clear

1031 citation(s) found for "Clark, AS".

Facial Numbness and Paresthesias Resolved with Anterior Cervical Decompression and Fusion
Francois, Elvis L. , Clark, Nicholas J. , Freedman, Brett A.

Mayo Clinic

JBJS Case Connector | July 11, 2019 | Volume: 9 | Issue: 3 | Pages: e0294-e0294

10.2106/jbjs.cc.18.00294 | PMID 31274646 Get It

Case: We report 3 patients with classic trigeminal neuropathy (TN) findings, which were due to compressive cervical radiculopathy, and provide a brief anatomic explanation for this association. In each case, left-sided disk herniation between the C5 and C7 levels caused TN and classic (dermatome appropriate) cervical radicular findings, all of which resolved with anterior cervical decompression and fusion (ACDF). Conclusions: To our knowledge, this is the first report of TN caused by radicular compression in the caudal subaxial (C5-C7) cervical spine, which resolved after ACDF.
Molecular characterization of known and novel ACVR1 variants in phenotypes of aberrant ossification
Gupta, Aditi , Zimmermann, Michael T. , Sigafoos, Ashley N. , Macklin, Sarah , Pignolo, Robert J. , Klee, Eric W. , Macklin, Sarah K, Urrutia, Raul A, Zimmermann, Michael T , Wang, Haitao , Broski, Stephen M. , Urrutia, Raúl , Clark, Karl J. , Atwal, Paldeep S

Mayo Clinic

American Journal of Medical Genetics Part A | June 26, 2019 | Volume: 179 | Issue: 9 | Pages: 1764-1777

10.1002/ajmg.a.61274 | PMID 31240838 Get It

AbstractDiffuse idiopathic skeletal hyperostosis (DISH) is a disorder principally characterized by calcification and ossification of spinal ligaments and entheses. Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disabling disorder characterized by progressive ossification of skeletal muscle, fascia, tendons, and ligaments. These conditions manifest phenotypic overlap in the ossification of tendons and ligaments. We describe herein a patient with DISH, exhibiting heterotopic ossification of the posterior longitudinal ligament where clinical whole exome sequencing identified a variant within ACVR1, a gene implicated in FOP. This variant, p.K400E, is a novel variant, not identified previously, and occurs in a highly conserved region across orthologs. We used sequence‐based predicative algorithms, molecular modeling, and molecular dynamics simulations, to test the potential for p.K400E to alter the structure and dynamics of ACVR1. We applied the same modeling and simulation methods to established FOP variants, to identify the detailed effects that they have on the ACVR1 protein, as well as to act as positive controls against which the effects of p.K400E could be evaluated. Our in silico molecular analyses support p.K400E as altering the behavior of ACVR1. In addition, functional testing to measure the effect of this variant on BMP‐pSMAD 1/5/8 target genes was carried out which revealed this variant to cause increased ID1 and Msx2 expression compared with the wild‐type receptor. This analysis supports the potential for the variant of uncertain significance to contribute to the patient's phenotype.
National trends in prescription drug expenditures and projections for 2019
Schumock, Glen T., Stubbings, JoAnn , Hoffman, James M. , Wiest, Michelle D., Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Tichy, Eric M. , Cuéllar, Sandra , Clark, John Spencer , Matusiak, Linda M., Hunkler, Robert J., Vermeulen, Lee C.

Mayo Clinic

American Journal of Health-System Pharmacy | June 14, 2019 | Volume: 76 | Issue: 15 | Pages: 1105-1121

10.1093/ajhp/zxz109 | PMID 31199861 Get It

AbstractPurposeHistorical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2019 in nonfederal hospitals, clinics, and overall (all sectors).MethodsDrug expenditure data through calendar year 2018 were obtained from the IQVIA National Sales Perspectives database and analyzed. New drug approvals, patent expirations, and other factors that may influence drug spending in hospitals and clinics in 2019 were also reviewed. Expenditure projections for 2019 for nonfederal hospitals, clinics, and overall (all sectors) were made through a combination of quantitative analyses and expert opinion.ResultsU.S. prescription sales in calendar year 2018 totaled $476.2 billion, a 5.5% increase from 2017 spending. The top 3 drugs by expenditures were adalimumab ($19.1 billion), insulin glargine ($9.3 billion), and etanercept ($8.0 billion). Prescription expenditures in nonfederal hospitals totaled $35.8 billion, a 4.8% increase from 2017. Expenditures in clinics in 2018 increased by 13.0% to $80.5 billion. The increase in spending in nonfederal hospitals was largely driven by new products and increased utilization of existing products. The list of the top 25 drugs by expenditures in nonfederal hospitals and clinics was dominated by specialty drugs.ConclusionWe predict continued moderate growth of 4–6% in overall drug expenditures (across the entire U.S. market). We expect the clinic sector to continue to experience high (11–13%) growth in drug spending in 2019. Finally, for nonfederal hospitals we anticipate growth in the range of 3–5%. These estimates are at the national level. Health-system pharmacy leaders should carefully examine local drug utilization patterns to determine their own organization’s anticipated spending in 2019.
Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients
Whitmire, Paula , Rickertsen, Cassandra , Lorence, Julia, León, Gustavo De , Bayless, Spencer, Clark-Swanson, Kamala , Corpuz, Christina, Angeles, Christine Paula Lewis-de los, Bendok, Bernard R. , Vora, Sujay A., Mrugała, Maciej M. , Hu, Leland , Porter, Alyx B. , Kumthekar, Priya , Johnston, Sandra K. , Egan, Kathleen M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Hawkins‐Daarud, Andrea , Carrasco, Eduardo, Curtin, Lee , Peeri, Noah Charles , Gonzalez‐Cuyar, Luis F. , Wang, Lei G. , Gatenby, Robert A. , Rubin, Joshua B

Mayo Clinic

No container title available | June 10, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.10177/v1 Get It

Abstract Background: Sex is recognized as a significant determinant of outcome among glioblastoma patients, but the relative prognostic importance of glioblastoma features has not been thoroughly explored for sex differences. Methods: Combining multi-modal MR images, biomathematical models, and patient clinical information, this investigation assesses which pretreatment variables have a sex-specific impact on the survival of glioblastoma patients (299 males and 195 females). Results: Among males, tumor (T1Gd) radius was a predictor of overall survival (HR=1.027, p=0.044). Among females, higher tumor cell net invasion rate was a significant detriment to overall survival (HR=1.011, p<0.001). Female extreme survivors had significantly smaller tumors (T1Gd) (p=0.010 t-test), but tumor size was not correlated with female overall survival (p=0.955 CPH). Both male and female extreme survivors had significantly lower tumor cell net proliferation rates than other patients (M p=0.004, F p=0.001, t-test). Additionally, extent of resection, tumor laterality, and IDH1 mutation status were also found to have sex-specific effects on overall survival. Conclusion: Despite similar distributions of the MR imaging parameters between males and females, there was a sex-specific difference in how these parameters related to outcomes.
An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant
Whitwell, Jennifer L. , Stevens, Chase A., Martin, Peter R. , Botha, Hugo , Spychalla, Anthony J., Senjem, Matthew L. , Jack, Clifford R. , Ali, Farwa , Hassan, Anhar , Josephs, Keith A. , Strand, Edythe A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M. , Utianski, Rene L. , Schwarz, Christopher G.

Mayo Clinic

Movement Disorders Clinical Practice | May 30, 2019 | Volume: 6 | Issue: 6 | Pages: 452-461

10.1002/mdc3.12796 | PMID 31392246 Get It

ABSTRACTBackgroundThe Movement Disorder Society clinical criteria for progressive supranuclear palsy (PSP) provide a framework for assessing the presence/severity of clinical symptoms and define a speech/language variant of PSP.ObjectivesTo evaluate the clinical criteria in a cohort of speech/language patients with longitudinal follow‐up.MethodsA total of 52 patients presenting with progressive apraxia of speech and/or agrammatic aphasia were followed longitudinally for up to 6 visits with clinical assessments and magnetic resonance imaging. We assessed oculomotor, postural instability, and akinesia diagnostic levels and determined whether patients met criteria for possible PSP‐speech/language or probable PSP at each visit. Kaplan‐Meier curves assessed time‐to‐event probabilities according to age. Statistical parametric mapping and midbrain volume were assessed according to disease progression.ResultsFew PSP symptoms were observed early in the disease, with oculomotor abnormalities and falls first observed 2 years after onset. Falls were more common than vertical supranuclear gaze palsy. Bradykinesia and rigidity commonly developed but axial was rarely greater than appendicular rigidity. During follow‐up, 54% met criteria for possible PSP‐speech/language, 38% for probable PSP‐Richardson's syndrome, and 38% for probable PSP‐parkinsonism, most commonly 6 to 6.9 years after onset. The probability of developing PSP was greater when onset was at an age older than 70 years. Patients who progressed to probable PSP had more parkinsonism and oculomotor impairment at baseline and greater midbrain atrophy when compared with those who did not develop probable PSP.ConclusionsSymptoms typical of PSP commonly develop in patients presenting with a progressive speech/language disorder. Older age appears to be an important prognostic factor in these patients.
Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy.
Roeland, Eric , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Clark-Snow, Rebecca, Wickham, Rita S., Binder, G. , Sebastiani, Silvia , Papademetriou, Eros , Schmerold, Luke, Navari, Rudolph M. , Leblanc, Thomas , Roeland, Eric J , Sebastiani, Silvia, Potluri, Ravi C.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e23108-e23108

10.1200/jco.2019.37.15_suppl.e23108 Get It

e23108 Background: ASCO antiemetic guidelines recommend upfront triple prophylaxis (NK1 receptor antagonist (RA) + 5HT3 RA + dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC). Physicians exhibit high variation in HEC guideline adherence, principally involving inclusion of NK1 RA. Whether adherence is associated with selection of the specific 5HT3 RA agent remains inadequately studied. Methods: In the IBM Explorys electronic health record database, we used procedure and diagnosis codes to identify HEC courses and related nausea/vomiting (NV) from 2012 to 2018. We defined HEC guideline adherence as triple prophylaxis at chemotherapy initiation. We assigned HEC courses for ≥ 7 day cycles of cisplatin or anthracycline + cyclophosphamide (AC), or carboplatin (≥ 14 day cycles as a proxy for AUC ≥ 4) to prescribing oncologists based on encounter frequency. We categorized 5HT3 RA use of each physician treating ≥ 5 HEC courses based on their most commonly used 5HT3 and performed descriptive statistics. Results: Of 12,262 HEC courses, 57% involved physicians having greater use of ondansetron (OND) (mean OND to palonosetron (PALO) ratio of 3.9:1). These courses had lower guideline adherence (due to NK1 RA omission) and higher rates of NV for combined HEC, AC, and carboplatin. NV rates for cisplatin did not vary by 5HT3 agent used. Courses involving physicians with greater PALO use (mean OND:PALO ratio of 0.2:1) had superior adherence and NV rates, despite involving a slightly higher risk population (younger and/or female). Conclusions: According to HEC antiemetic guidelines, NK1 RA use should occur independent of 5HT3 RA agent selection. However, we observed less NK1 RA use where OND was preferred, which may have caused the observed higher rates of NV with OND. Further evaluation should assess whether pharmacy cost minimization is a driver of both OND preference and NK1 omission in HEC. [Table: see text]
Ulnar head replacement and sigmoid notch resurfacing arthroplasty with minimum 12-month follow-up
Clark, Nicholas J. , Munaretto, Nicholas , Elhassan, Bassem T. , Elhassan, Bassem T. , Kakar, Sanjeev

Mayo Clinic

Journal of Hand Surgery (European Volume) | May 23, 2019 | Volume: 44 | Issue: 9 | Pages: 957-962

10.1177/1753193419850116 | PMID 31117865 Get It

Our study aimed to report the short-term outcomes of patients who underwent partial ulnar head replacement and distal radial ulnar joint interposition arthroplasty. From 2012 to 2016, nine patients underwent this procedure with mean follow-up of 27 months (range 12–55). Seven of the nine patients had previously undergone surgical intervention on the ipsilateral wrist. The procedure resulted in substantial improvements in pain and function. Mayo Wrist Score improved from 37 preoperatively to 73 postoperatively, and six patients achieved a good or excellent outcome. Visual analogue pain scores decreased from 7 preoperatively to 1 postoperatively. Grip improved from 20 kg preoperatively to 30 kg postoperatively. There was no significant change in wrist range of motion. Two patients underwent revision surgery to improve wrist motion. We conclude that over short-term follow-up the procedure provides a feasible option for distal radial ulnar joint arthritis. Level of evidence: IV
Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome
Tetzloff, Katerina A. , Botha, Hugo , Martin, Peter R. , Senjem, Matthew L. , Gunter, Jeffrey L. , Spychalla, Anthony J., Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Strand, Edythe A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Duffy, Joseph R. , Clark, Heather M. , Utianski, Rene L. , Machulda, Mary M. , Schwarz, Christopher G. , Reid, Robert I. , Knopman, David S.

Mayo Clinic

Brain | May 17, 2019 | Volume: 142 | Issue: 8 | Pages: 2466-2482

10.1093/brain/awz157 | PMID 31199471 Get It

Abstract Agrammatic aphasia affects grammatical language production and can result from a neurodegenerative disease. Although it typically presents with concomitant apraxia of speech, this is not always the case. Little is known about the clinical course and imaging features of patients that present with agrammatism in the absence of apraxia of speech, which we will refer to as progressive agrammatic aphasia. We aimed to make a detailed description of the longitudinal clinical, linguistic, and neuroimaging features of a cohort of 11 patients with progressive agrammatic aphasia to provide a complete picture of this syndrome. All patients underwent detailed speech and language, neurological and neuropsychological assessments, 3 T structural and diffusion tensor imaging MRI, 18F-fluorodeoxyglucose and Pittsburgh compound B PET. The 11 patients were matched by age and gender to 22 patients who had mixed apraxia of speech and agrammatism. The progressive agrammatic aphasia patients performed abnormally on tests of language, general cognition, executive function, and functional ability at baseline and declined in these measures over time. Only two patients eventually developed apraxia of speech, while parkinsonism was absent-to-mild throughout all visits for all patients. When compared to the patients with mixed apraxia of speech and agrammatism, the patients with progressive agrammatic aphasia performed better on tests of motor speech and parkinsonism but more poorly, and declined faster over time, on tests of general aphasia severity, agrammatism, and naming. The patients with progressive agrammatic aphasia also showed different neuroimaging abnormalities, with greater atrophy, hypometabolism and white matter tract degeneration in the prefrontal and anterior temporal lobes compared to patients with mixed apraxia of speech and agrammatism. These differences were more pronounced as the disease progressed. These results demonstrate that progressive agrammatic aphasia has a different clinical disease course and different underlying neuroanatomical abnormalities than patients with the more common syndrome of mixed agrammatism and apraxia of speech. This supports the distinction of progressive agrammatic aphasia and has implications for the classification of patients with agrammatic aphasia.
Resolution of Postsurgical Diplopia, Paresthesia, and Weakness Following Inpatient Massage Therapy: A Case Report
Hauschulz, Jennifer L. , Clark, Stephanie , Bauer, Brent A. , Chon, Tony Y. , Hauschulz, Jennifer , Bauer, Brent, Chon, Tony

Mayo Clinic

Global Advances in Health and Medicine | May 16, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119852396 | PMID 31192054 Get It

Massage therapy is utilized in hospitals for patients experiencing pain, anxiety, sleeplessness, among other symptoms. Postsurgical pain is one of the most common reasons massage therapy is ordered. We present a case of a 45-year-old woman who underwent ventral hernia repair. Postoperative day 2, she began to experience multiple symptoms, including double-vision, left-sided facial numbness, tremors, pain, and weakness in her left fingers, arm, and leg. A static magnetic resonance image of the brain and cervical spine were obtained, which revealed disc protrusions at C3/C4, C5/C6, C6/C7, and mild deformity of the spinal cord. The patient’s pain was difficult to control and she was unable to be weaned from intravenous pain medication. Massage therapy was ordered on postoperative days 6 and 7. During both massage sessions, as upper neck muscle tension was reduced, the therapist and patient observed several audible “pops” of the cervical spine with immediate relief of symptoms. In this particular case, massage therapy, though requested to address pain, had a secondary benefit in relieving her diplopia, left-sided facial numbness, tremors, and weakness. Although the mechanism of action is not clear, this case highlights the significant secondary beneficial effects that often occur with massage therapy.
Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL
Suleiman, Linda I. , Price, ER, Singhrao, Ruby , Albain, KS, Chien, AJ, Forero‐Torres, Andres , Wallace, AM, Ellis, ED, Elias, AD, Lang, JE, Lu, Jinghui , Han, HS, Clark, AS, Korde, LA, Nanda, Rita , Northfelt, DW, Khan, QJ, Viscusi, RK, Euhus, DM, Edmiston, KK, Chui, SY, Kemmer, KA, Wood, WC, Liu, MC, Olopade, OI, Leyland-Jones, B, Moulder, SL, Rugo, HS, Schwab, Richard B. , Lo, Simon S. , Beckwith, Heather , Berry, DA, Asare, SM, Esserman, LJ, Boughey, JC , Mukhtar, RA, Khan, Qamar J. , Silverstein, J, Suleiman, L, Yau, Christina , Price, Erin, Yee, Douglas , DeMichele, Angela , Isaacs, Claudine , Pusztai, Lajos , Park, JW, Tripathy, Debu , Helsten, Teresa L.

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: P2-14-01-P2-14-01

10.1158/1538-7445.sabcs18-p2-14-01 Get It

Abstract Background: In women with breast cancer receiving neoadjuvant chemotherapy, residual cancer burden (RCB) predicts distant recurrence and survival. In those with high risk tumors, locoregional recurrence (LRR) remains a concern, and has been associated with type of local therapy received. We evaluated the impact of local therapy on LRR in the ISPY-2 TRIAL. Methods: Data were analyzed in Stata 14.2, using Chi2 test, log rank test, and a Cox proportional hazards model. RCB was considered a categorical variable (0/1 versus 2/3), as described in prior publications. Breast surgery categories were lumpectomy +/- radiotherapy, or mastectomy +/- radiotherapy. Axillary surgery was defined as sentinel lymph node (SLN) surgery (≤6 nodes removed) or axillary dissection (&gt;6 nodes). Results: Follow up data from the I-SPY2 TRIAL were available for 630 patients (median follow up 2.76 yrs, range 0.4-7.2). Type of local therapy was significantly associated with clinical stage at presentation, with stage III patients most frequently undergoing mastectomy + radiation (p&lt;0.001). Women with higher RCB were more likely to undergo mastectomy than those with lower RCB (61.3% vs 48.8% mastectomy rate, p=0.002), and more likely to receive adjuvant radiotherapy (62.0% vs 53.9%, p=0.048). There was no association between clinical stage, type of surgery, or radiotherapy and LRR (Table). Higher RCB was significantly associated with LRR, with 3 year locoregional recurrence free rate of 95.1% in RCB 0/1 versus 89.9% in RCB 2/3 (p=0.003). In a Cox model adjusting for clinical stage, tumor subtype, surgical therapy, RCB status, nodal radiation, and age, significant predictors for LRR were tumor subtype and RCB status. Hazard ratio (HR) for LRR in those with RCB 0/1 was 0.39 compared to those with RCB 2/3 (95% CI 0.17-0.87, p=0.021). There was no difference in LRR between breast conservation and mastectomy; within the breast conservation group, those who had lumpectomy alone had higher hazard of LRR compared to those having lumpectomy + radiation (HR 3.1, 95% CI 1.1-9.2, p=0.043). Conclusions: Extent of surgical therapy was not associated with local tumor control, regardless of advanced tumor stage at presentation. Rather, tumor biology and response to therapy were the best predictors of LRR. These data highlight the opportunity to minimize the morbidity of extensive surgical therapy for patients with excellent response to systemic therapy. LRR rates by clinical features and treatment status FrequencyLRR RateP valueClinical Stage 0.5I240 (47.5%)5.8% II185 (36.6%)8.7% III80 (15.8%)6.3% Tumor Subtype 0.014ER+PR+Her2-161 (26.4%)3.1% ER+PR-Her2-56 (9.2%)3.6% Her2+176 (28.9%)6.3% Triple negative216 (35.5%)11.1% Local therapy 0.169Lumpectomy85 (13.5%)11.8% Lumpectomy with radiation198 (31.4%)5.6% Mastectomy173 (27.5%)5.2% Mastectomy with radiation174 (27.6%)8.6% Axillary surgery 0.23None5 (0.8%)20% SLN329 (52.2%)5.8% ALND296 (47%)8.5% Axillary radiation 0.535Yes42 (6.7%)9.5% No588 (93.3%)7.0% Axillary management 0.2No surgery or radiation5 (0.8%)20.0% SLN312 (50%)5.3% SLN+Axillary radiation17 (2.7%)8.3% ALND271 (43%)10.3% ALND+Axillary radiation25 (4%)5.4% RCB 0.0020/1293 (50.1%)3.8% 2/3292 (49.9%)10.3% Citation Format: Silverstein J, Suleiman L, Yau C, Price ER, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain KS, Chien AJ, Forero-Torres A, Wallace AM, Pusztai L, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, I-SPY 2 TRIAL Consortium, Berry DA, Asare SM, Esserman LJ, Boughey JC, Mukhtar RA. The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-01.